Premium
Immune response of patients with recurrent aphthous stomatitis challenged with a symbiotic
Author(s) -
Mimura Maria Angela Martins,
Borra Ricardo Carneiro,
Hirata Cleonice Hitomi Watashi,
Penido Norma
Publication year - 2017
Publication title -
journal of oral pathology and medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.887
H-Index - 83
eISSN - 1600-0714
pISSN - 0904-2512
DOI - 10.1111/jop.12621
Subject(s) - recurrent aphthous stomatitis , immune system , immunology , medicine , bifidobacterium bifidum , bifidobacterium , serology , fructooligosaccharide , pathogenesis , lactobacillus , stomatitis , biology , antibody , biochemistry , bacteria , genetics
Background There are indications that Th1 polarization of immune response plays an important role in the pathogenesis of recurrent aphthous stomatitis ( RAS ), and that the use of probiotics can stimulate immune regulatory activity, influencing the course of the disease. The aim of this study was to characterize the initial immune profile of RAS patients and evaluate clinical and serological response following a challenge with symbiotic treatment containing fructooligosaccharide, Lactobacillus, and Bifidobacterium . Methods The immune responses of the 45 patients with RAS , submitted to symbiotic or placebo for 120 days, in relation to 30 RAS ‐free controls, were evaluated over a period of 6 months. Peripheral blood was collected from all patients at 0 (T0), 120 (T4), and 180 days (T6) after the start of treatment and Th1 ( IL 12‐p70, IFN ‐γ), Th2 ( IL ‐4), Treg ( IL ‐10), Th17 ( IL ‐17A), inflammatory ( TNF ‐α, IL ‐6)‐associated cytokines, and clinical parameters were quantified. Results At T0, significant differences were found in the serological levels of the IFN ‐γ, IL ‐4, and IL ‐6 cytokines of the RAS patients in comparison with the controls. It was observed that the cytokine profile of the RAS group was comprised of 2 distinct clusters: a pure Th2 and a Mixed (Th1/Th2) subtype and that symbiotic treatment induced an improvement in pain and an increase in IFN ‐γ levels, producing a reduction in Th2 response. Conclusions In RAS , symbiotic treatment based on a fructooligosaccharide, Lactobacillus, and Bifidobacterium composition produced an alteration in the Th2 serological immune profile in the direction of Th1 and improved pain symptomatology.